The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.
|Articles|March 9, 2012
Dr. Bimal Patel Discusses the Rising Costs of Generic Drugs
Bimal Patel, PharmD, MS, Director, Health Outcomes Research, MedImpact Healthcare Systems, Inc., discusses MedImpact's work to identify, analyze, and evaluate generic medications that have become significantly expensive, and effective strategies for managing these costs.
Advertisement
Bimal Patel, PharmD, MS, Director, Health Outcomes Research, MedImpact Healthcare Systems, Inc., discusses MedImpact’s work to identify, analyze, and evaluate generic medications that have become significantly expensive, and effective strategies for managing these costs.
Dr. Patel also discusses the importance of communication among pharmacy benefit managers, plan sponsors, and physicians as generic drug costs continue to rise.
Advertisement
Related to this article
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
FDA Approves First Heart Valve to Keep Pace With Children's Growth
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5